EUVIMEDEUVIMED entdecken
Open Access

TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas

Yanting Liu, Fang Liu, Chuanbao Li, Tao Zhang, Tianyi Han, Yuting Dai, Ning Huang, Hao Tang, Xiaobin Wang, Shaojian Lin iD, Li Xue, Zhe Bao Wu iD

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Yanting Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Drug Resistance, Neoplasm, Ribonucleoproteins, Adenoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pituitary adenomas (PAs) are common intracranial tumors and the TRIM family plays a crucial role in cell proliferation and therapeutic resistance of tumors. However, the role of the TRIM family in PAs is not well recognized.

Methods

CRISPR screening explored the role of the TRIM family in cell proliferation and drug resistance in PAs. In vitro and in vivo experiments were performed to evaluate the effects of Tripartite Motif Containing 21 (TRIM21). RNA-sequencing, mass spectrometry, immunoprecipitation, and ubiquitination experiments were performed to explore the molecular mechanism. NanoBiT assays were used to screen the drugs reducing TRIM21 expression.

Results

CRISPR-Cas9 screens identified that TRIM21 facilitated cell proliferation and drug resistance in PAs. Mechanistically, TRIM21 interacted with ERK1/2 through PRY-SPRY domain, leading to ERK1/2 K27-linked ubiquitination. The ERK1/2 ubiquitination promotes the interaction between ERK1/2 and MEK1/2, thereby facilitating the phosphorylation of ERK1/2. However, an excess presence of TRIM21 suppressed the phosphorylation of ERK1/2 and cell proliferation via activating ERK1/2 negative feedback pathways. Importantly, TRIM21 was upregulated in dopamine-resistant prolactinomas and cabergoline-resistant MMQ cells. Furthermore, drug screening identified that Fimepinostat and Quisinostat, can reduce the protein levels of TRIM21, inhibit tumor progression, and increase drug sensitivity.

Conclusions

TRIM21 may represent a therapeutic target for tumors, and inhibiting TRIM21 could be a potential strategy for tumor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsDrug Resistance, NeoplasmRibonucleoproteinsAdenomaMAP Kinase Signaling SystemHumansCell ProliferationAnimalsUbiquitinationMicePhosphorylationTumor Cells, CulturedMice, NudeMaleXenograft Model Antitumor AssaysSS-A Antigen

Stichwörter der Autor:innen

ERK1/2TRIM21cell proliferationpituitary adenomasubiquitination

Substanzen

RibonucleoproteinsSS-A Antigen

Autor:innen und Institutionen

  • Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Me…
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
  • The First Affiliated Hospital, Henan University, Kaifeng, P.R. China.
  • Department of Neurosurgery, Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Shaojian Lin, Zhe Bao Wu

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds
  • Shanghai Municipal Health Commission
  • National Research Center for Translational Medicine
  • Shanghai Municipal Science and Technology Commission

Zitieren

APA

Liu, Y., Liu, F., Li, C., Zhang, T., Han, T., Dai, Y., Huang, N., Tang, H., Wang, X., Lin, S., Xue, L., & Wu, Z. B. (2025). TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae241

Vancouver

Liu Y, Liu F, Li C, Zhang T, Han T, Dai Y, et al. TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae241

BibTeX
@article{Liu2025,
  author = {Liu, Yanting and Liu, Fang and Li, Chuanbao and Zhang, Tao and Han, Tianyi and Dai, Yuting and Huang, Ning and Tang, Hao and Wang, Xiaobin and Lin, Shaojian and Xue, Li and Wu, Zhe Bao},
  title = {TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae241}
}
Kostenlos starten →